Latest Codexis Inc (CDXS) Headlines Codexis Rep
Post# of 42
Posted On: 03/13/2014 6:31:52 AM
Latest Codexis Inc (CDXS) Headlines
Codexis Reports Fourth Quarter and Full Year 2013 Results
GlobeNewswire - Tue Mar 11, 3:04PM CDT
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced its financial results for the fourth quarter and year ended December 31, 2013.
Dyadic Withdraws Notice Of Breach Letter Relating To Its C1 License Agreement With Codexis
PR Newswire - Mon Mar 10, 3:38PM CDT
Dyadic International, Inc. ("Dyadic")(OTC Pink: DYAI), a global biotechnology company, announced today that it received notice from Codexis, Inc. that it will no longer be pursuing its advanced biofuels program. This notice is consistent with Codexis' previous public announcement on November 12, 2013 that it was immediately winding down its advanced biofuels program.
Codexis Appoints Biopharmaceuticals Industry Veteran, Patrick Yang, Ph.D., to Board of Directors
GlobeNewswire - Thu Feb 27, 6:45AM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced the appointment of Patrick Yang, Ph.D., to its board of directors. Dr. Yang brings significant experience in pharmaceutical manufacturing and process development to the Codexis board, following several executive leadership roles within the pharmaceutical industry.
Gas Exploration to Start April in Tanga
by Nestory Ngwega - All Africa Global Media - Wed Feb 26, 12:33AM CST
TANGA Regional Commissioner Ms Chiku Gallawa announced that exploration of gas and oil in the region's coastal belt will start in April, this year. Ms Gallawa said the exercise was initially scheduled to start last month, but was delayed to enable the exploration company have more time for preparations.
Codexis to Announce Fourth Quarter and Fiscal Year 2013 Financial Results on March 11, 2014
GlobeNewswire - Tue Feb 25, 3:02PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced it will host a live conference call and audio webcast on Tuesday, March 11, 2014 at 4:30 p.m. Eastern Time to discuss its fourth quarter and fiscal year 2013 financial results for the period ended December 31, 2013. The call and webcast will follow the release of fourth quarter and fiscal year financial results after market close. A recorded version of the call will be available approximately one hour after the call on the Investors section of the company's website, www.codexis.com, and will be archived for up to 30 days.
Aurigene and Pierre Fabre Pharmaceuticals Announce a Licensing Agreement for a New Cancer Therapeutic in Immuno-oncology: AUNP12, an Immune Checkpoint Modulator Targeting the PD-1 Pathway
PR Newswire - Thu Feb 13, 2:14AM CST
Pierre Fabre, the third largest French pharmaceutical company, and Aurigene, a leading biotech company based in India, today announced that the two companies have entered into a collaborative license, development and commercialization agreement granting Pierre Fabre global Worldwide rights (excluding India) to a new immune checkpoint modulator, AUNP-12.
Codexis to Present at 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 04, 9:49PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and complex chemistry industries, today announced that John Nicols, President and CEO of Codexis, will present a company overview at the 16 Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 1:00 p.m. ET in New York City.
5 Stocks Under $10 Set to Soar
at The Street - Thu Jan 23, 1:15PM CST
These under-$10 stocks look ready to trade higher from current levels.
2 Biotech Stocks Under $10 Triggering Breakouts
at The Street - Wed Jan 08, 6:00AM CST
Keep these under-$10 biotech stock on your radar.
Global Specialty Enzymes Strategic Business Report 2013-2018: Proteases, Polymerases, Carbohydrases & Others
M2 - Tue Nov 19, 9:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/tm4s6c/specialty_enzymes#summary) has announced the addition of the "Specialty Enzymes - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. This report analyzes the worldwide markets for Specialty Enzymes in US$ Million by the following Product Segments: - Proteases - Polymerases - Carbohydrases - Other Specialty Enzymes. Specific end-use segments also analyzed are: - Pharmaceuticals & Diagnostics - Research/Biotechnology - Others. The report profiles 43 companies including many key and niche players such as: - Advanced Enzymes Technologies Limited - Advanced Vital Enzymes Ltd. - Amano Enzyme Inc. - AST Enzymes - Biocatalysts Ltd. - BBI Solutions - Chr. Hansen Holding AS - Codexis, Inc. - Genzyme Corporation - Life Technologies Corporation - Meteoric Life Sciences - National Enzyme Company - ROCHE Holding, Inc. - Specialty Enzymes & Biotechnologies Co. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Market Trends, Issues And Drivers 3. Overall (Industrial And Specialty) Enzymes Market: A Macro Perspective 4. Product Overview 5. Product Introductions/Innovations 6. Recent Industry Activity 7. Focus On Select Global Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 43 (including Divisions/Subsidiaries - 48) - The United States (23) - Canada (1) - Japan (4) - Europe (11) - - France (1) - - Germany (1) - - The United Kingdom (3) - - Spain (1) - - Rest of Europe (5) - Asia-Pacific (Excluding Japan) (9) For more information visit http://www.researchandmarkets.com/research/tm...es#summary
Codexis Reports Third Quarter 2013 Results and Business Update
Business Wire - Tue Nov 12, 3:01PM CST
-- Conference call today at 4:30 pm ET --
Codexis Inc names Dr. Greg Hughes as VP of Strategic Alliance & Product Development
M2 - Wed Nov 06, 5:14AM CST
Enzyme company Codexis Inc (NasdaqGS:CDXS) revealed on Tuesday the addition of Dr. Greg Hughes, Ph.D., as vice president of its Strategic Alliance & Product Development with effect from 28 October 2013.
Codexis Appoints Greg Hughes, Ph.D., as Vice President, Strategic Alliance & Product Development
Business Wire - Tue Nov 05, 3:01PM CST
Codexis, Inc. (NASDAQ: CDXS), a developer of engineered enzymes for pharmaceutical, biofuel and chemical production, today announced the appointment of Greg Hughes, Ph.D., as Vice President, Strategic Alliance & Product Development, effective October 28, 2013. Dr. Hughes spent the last 11 years in Process Chemistry at Merck with a primary focus in developing and implementing biocatalysis technology.
Codexis to Announce Third Quarter 2013 Financial Results on November 12, 2013
Business Wire - Mon Nov 04, 3:01PM CST
Codexis, Inc. (NASDAQ: CDXS), a developer of engineered enzymes for pharmaceutical, biofuel and chemical production, today announced it will host a live conference call and audio webcast on Tuesday, November 12, 2013 at 4:30 p.m. Eastern Time to discuss its third quarter 2013 financial results for the period ended September 30, 2013. The call and webcast will follow the release of third quarter financial results after market close. A recorded version of the call will be available approximately one hour after the call on the Investors section of the company's website, www.codexis.com, and will be archived for up to 30 days.
New Steel Boiler from Harsco - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 08, 5:30PM CDT
Harsco recently introduced a new stainless steel boiler with state-of-the-art cost-efficient solution for its customers.
Harsco Sells Infra Business to JV - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 17, 11:50AM CDT
Harsco Corporation recently announced the sale of its Infrastructure division to its own joint venture.
Grainger's August Sales Up 4% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 13, 2:40PM CDT
Grainger reported a 4% year-over-year increase in sales in Aug 2013.
Codexis, Inc Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 03, 1:15AM CDT
Codexis, Inc Enters Oversold Territory
Stock to Watch: Codexis Down 8.4% (CDXS)
Comtex SmarTrend(R) - Mon Aug 12, 10:16AM CDT
Codexis (NASDAQ:CDXS) is one of today's worst performing low-priced stocks, down 8.4% to $2.06 on 2.2x average daily volume. Thus far today, Codexis has traded 468,000 shares, vs. average volume of 212,000 shares per day. The stock has underperformed the Dow (-8.4% to the Dow's 0.0%) and underperformed the S&P 500 (-8.4% to the S&P's -0.1%) during today's trading.
Codexis Reports Second Quarter 2013 Results
Business Wire - Fri Aug 09, 3:15PM CDT
Codexis, Inc. (NASDAQ: CDXS), a developer of engineered enzymes for pharmaceutical, biofuel and chemical production, today announced financial results for the second quarter ended June 30, 2013.
Codexis Reports Fourth Quarter and Full Year 2013 Results
GlobeNewswire - Tue Mar 11, 3:04PM CDT
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced its financial results for the fourth quarter and year ended December 31, 2013.
Dyadic Withdraws Notice Of Breach Letter Relating To Its C1 License Agreement With Codexis
PR Newswire - Mon Mar 10, 3:38PM CDT
Dyadic International, Inc. ("Dyadic")(OTC Pink: DYAI), a global biotechnology company, announced today that it received notice from Codexis, Inc. that it will no longer be pursuing its advanced biofuels program. This notice is consistent with Codexis' previous public announcement on November 12, 2013 that it was immediately winding down its advanced biofuels program.
Codexis Appoints Biopharmaceuticals Industry Veteran, Patrick Yang, Ph.D., to Board of Directors
GlobeNewswire - Thu Feb 27, 6:45AM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced the appointment of Patrick Yang, Ph.D., to its board of directors. Dr. Yang brings significant experience in pharmaceutical manufacturing and process development to the Codexis board, following several executive leadership roles within the pharmaceutical industry.
Gas Exploration to Start April in Tanga
by Nestory Ngwega - All Africa Global Media - Wed Feb 26, 12:33AM CST
TANGA Regional Commissioner Ms Chiku Gallawa announced that exploration of gas and oil in the region's coastal belt will start in April, this year. Ms Gallawa said the exercise was initially scheduled to start last month, but was delayed to enable the exploration company have more time for preparations.
Codexis to Announce Fourth Quarter and Fiscal Year 2013 Financial Results on March 11, 2014
GlobeNewswire - Tue Feb 25, 3:02PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced it will host a live conference call and audio webcast on Tuesday, March 11, 2014 at 4:30 p.m. Eastern Time to discuss its fourth quarter and fiscal year 2013 financial results for the period ended December 31, 2013. The call and webcast will follow the release of fourth quarter and fiscal year financial results after market close. A recorded version of the call will be available approximately one hour after the call on the Investors section of the company's website, www.codexis.com, and will be archived for up to 30 days.
Aurigene and Pierre Fabre Pharmaceuticals Announce a Licensing Agreement for a New Cancer Therapeutic in Immuno-oncology: AUNP12, an Immune Checkpoint Modulator Targeting the PD-1 Pathway
PR Newswire - Thu Feb 13, 2:14AM CST
Pierre Fabre, the third largest French pharmaceutical company, and Aurigene, a leading biotech company based in India, today announced that the two companies have entered into a collaborative license, development and commercialization agreement granting Pierre Fabre global Worldwide rights (excluding India) to a new immune checkpoint modulator, AUNP-12.
Codexis to Present at 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 04, 9:49PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and complex chemistry industries, today announced that John Nicols, President and CEO of Codexis, will present a company overview at the 16 Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 1:00 p.m. ET in New York City.
5 Stocks Under $10 Set to Soar
at The Street - Thu Jan 23, 1:15PM CST
These under-$10 stocks look ready to trade higher from current levels.
2 Biotech Stocks Under $10 Triggering Breakouts
at The Street - Wed Jan 08, 6:00AM CST
Keep these under-$10 biotech stock on your radar.
Global Specialty Enzymes Strategic Business Report 2013-2018: Proteases, Polymerases, Carbohydrases & Others
M2 - Tue Nov 19, 9:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/tm4s6c/specialty_enzymes#summary) has announced the addition of the "Specialty Enzymes - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. This report analyzes the worldwide markets for Specialty Enzymes in US$ Million by the following Product Segments: - Proteases - Polymerases - Carbohydrases - Other Specialty Enzymes. Specific end-use segments also analyzed are: - Pharmaceuticals & Diagnostics - Research/Biotechnology - Others. The report profiles 43 companies including many key and niche players such as: - Advanced Enzymes Technologies Limited - Advanced Vital Enzymes Ltd. - Amano Enzyme Inc. - AST Enzymes - Biocatalysts Ltd. - BBI Solutions - Chr. Hansen Holding AS - Codexis, Inc. - Genzyme Corporation - Life Technologies Corporation - Meteoric Life Sciences - National Enzyme Company - ROCHE Holding, Inc. - Specialty Enzymes & Biotechnologies Co. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Market Trends, Issues And Drivers 3. Overall (Industrial And Specialty) Enzymes Market: A Macro Perspective 4. Product Overview 5. Product Introductions/Innovations 6. Recent Industry Activity 7. Focus On Select Global Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 43 (including Divisions/Subsidiaries - 48) - The United States (23) - Canada (1) - Japan (4) - Europe (11) - - France (1) - - Germany (1) - - The United Kingdom (3) - - Spain (1) - - Rest of Europe (5) - Asia-Pacific (Excluding Japan) (9) For more information visit http://www.researchandmarkets.com/research/tm...es#summary
Codexis Reports Third Quarter 2013 Results and Business Update
Business Wire - Tue Nov 12, 3:01PM CST
-- Conference call today at 4:30 pm ET --
Codexis Inc names Dr. Greg Hughes as VP of Strategic Alliance & Product Development
M2 - Wed Nov 06, 5:14AM CST
Enzyme company Codexis Inc (NasdaqGS:CDXS) revealed on Tuesday the addition of Dr. Greg Hughes, Ph.D., as vice president of its Strategic Alliance & Product Development with effect from 28 October 2013.
Codexis Appoints Greg Hughes, Ph.D., as Vice President, Strategic Alliance & Product Development
Business Wire - Tue Nov 05, 3:01PM CST
Codexis, Inc. (NASDAQ: CDXS), a developer of engineered enzymes for pharmaceutical, biofuel and chemical production, today announced the appointment of Greg Hughes, Ph.D., as Vice President, Strategic Alliance & Product Development, effective October 28, 2013. Dr. Hughes spent the last 11 years in Process Chemistry at Merck with a primary focus in developing and implementing biocatalysis technology.
Codexis to Announce Third Quarter 2013 Financial Results on November 12, 2013
Business Wire - Mon Nov 04, 3:01PM CST
Codexis, Inc. (NASDAQ: CDXS), a developer of engineered enzymes for pharmaceutical, biofuel and chemical production, today announced it will host a live conference call and audio webcast on Tuesday, November 12, 2013 at 4:30 p.m. Eastern Time to discuss its third quarter 2013 financial results for the period ended September 30, 2013. The call and webcast will follow the release of third quarter financial results after market close. A recorded version of the call will be available approximately one hour after the call on the Investors section of the company's website, www.codexis.com, and will be archived for up to 30 days.
New Steel Boiler from Harsco - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 08, 5:30PM CDT
Harsco recently introduced a new stainless steel boiler with state-of-the-art cost-efficient solution for its customers.
Harsco Sells Infra Business to JV - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 17, 11:50AM CDT
Harsco Corporation recently announced the sale of its Infrastructure division to its own joint venture.
Grainger's August Sales Up 4% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 13, 2:40PM CDT
Grainger reported a 4% year-over-year increase in sales in Aug 2013.
Codexis, Inc Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 03, 1:15AM CDT
Codexis, Inc Enters Oversold Territory
Stock to Watch: Codexis Down 8.4% (CDXS)
Comtex SmarTrend(R) - Mon Aug 12, 10:16AM CDT
Codexis (NASDAQ:CDXS) is one of today's worst performing low-priced stocks, down 8.4% to $2.06 on 2.2x average daily volume. Thus far today, Codexis has traded 468,000 shares, vs. average volume of 212,000 shares per day. The stock has underperformed the Dow (-8.4% to the Dow's 0.0%) and underperformed the S&P 500 (-8.4% to the S&P's -0.1%) during today's trading.
Codexis Reports Second Quarter 2013 Results
Business Wire - Fri Aug 09, 3:15PM CDT
Codexis, Inc. (NASDAQ: CDXS), a developer of engineered enzymes for pharmaceutical, biofuel and chemical production, today announced financial results for the second quarter ended June 30, 2013.
(0)
(0)Codexis Inc. (CDXS) Stock Research Links
Scroll down for more posts ▼